The following case report illustrates the successful use of physostigmine in the treatment of hallucinations and disorientation associated with an overdose of orphenadrine citrate (Norfiex).
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A 33 year old truck driver, taking Norfiex for cervical nerve root irritation, was admitted in coma four hours after the suspected consumption of 5,000 mg of Norfiex. He was hyper-refiexic, with extensor plantar responses, widely dilated pupils, sinus tachycardia of 120 beats/min and requiring a pharyngeal airway.
Following conservative management, he awoke six hours later. He was disorientated, hallucinating and vomited repeatedly. He became difficult to manage (pulling at his monitor leads, I/V infusion, and urethral catheter), and was subsequently given 2 mg physostigmine intravenously. Within two minutes he was rational, talkative and able to give a clear history. He confirmed his overdose, and complained of a dry throat.
His mydriasis, warm dry skin, and tachycardia persisted. A second dose of physostigmine (1'0 mg I/V) was given one and a half hours later when he again became restless and unmanageable, again with good effect.
Over the next three days all symptoms and signs except mydriasis had resolved.
DISCUSSION
Orphenadrine is a methyl derivative of the antihistamine diphenhydramine, and is given as the citrate or hydrochloride to ease the rigidity of Parkinsonism, and for skeletal muscle spasm. In therapeutic doses mild anticholinergic effects may be seen, the central ones being euphoria and drowsiness, and the peripheral ones being hesitancy of micturition, and a dry mouth.
Several cases of orphenadrine overdose have been reported but this appears to be the first in which physostigmine has been used to relieve the central anticholinergic features. It is well known that physostigmine can be used in the treatment of these same features associated with overdoses of hyoscine, atropine and the tricydic anti depressants. However, owing to its transient action (about 60 minutes), relapse into coma may occur. Other side effects of physostigmine include convulsion, bradycardia, and respiratory problems from hyper-salivation.
Physostigmine is thus not recommended for routine use in orphenadine overdose, but has a limited use in settling the restlessness and hallucinations of the anticholinergic crisis.
